Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Assets (2021 - 2025)

Amylyx Pharmaceuticals has reported Assets over the past 5 years, most recently at $332.6 million for Q4 2025.

  • Quarterly results put Assets at $332.6 million for Q4 2025, up 71.79% from a year ago — trailing twelve months through Dec 2025 was $332.6 million (up 71.79% YoY), and the annual figure for FY2025 was $332.6 million, up 71.79%.
  • Assets for Q4 2025 was $332.6 million at Amylyx Pharmaceuticals, down from $362.7 million in the prior quarter.
  • Over the last five years, Assets for AMLX hit a ceiling of $517.5 million in Q4 2023 and a floor of $105.6 million in Q4 2021.
  • Median Assets over the past 5 years was $332.2 million (2024), compared with a mean of $313.4 million.
  • Biggest five-year swings in Assets: surged 270.64% in 2022 and later tumbled 62.58% in 2024.
  • Amylyx Pharmaceuticals' Assets stood at $105.6 million in 2021, then surged by 270.64% to $391.5 million in 2022, then surged by 32.19% to $517.5 million in 2023, then tumbled by 62.58% to $193.6 million in 2024, then skyrocketed by 71.79% to $332.6 million in 2025.
  • The last three reported values for Assets were $332.6 million (Q4 2025), $362.7 million (Q3 2025), and $194.6 million (Q2 2025) per Business Quant data.